Diagnostic device specialist éclateral joined the Cancer Innovation in Wales seminar in November
Ellen Harradine, Product Design Engineer at éclateral, lead a discussion on the role of patient and public involvement in driving cancer care innovation on 12th November at 1pm.
The online session was held in partnership with the Academy of Medical Sciences and included a series of talks from industry experts.
Ellen said: “I’m honoured to have been asked to speak at the Cancer Innovation in Wales seminar in November. At éclateral, patient centricity is at the heart of everything we do, so exploring the ways in which patient advocacy groups and the general public’s involvement can be beneficial to cancer diagnosis is deeply important to us.”
Paul Ko Ferrigno, CEO and founder of éclateral, said: “It’s excellent to be a part of the conversation regarding cancer innovation and the role of patient engagement in its progression. Patient needs and experiences are key to progress and we place them at the heart of our ethos at éclateral, and I thoroughly enjoyed the discussion Ellen and so many other leaders in this space brought forward.”
This éclateral is committed to creating the next generation of diagnostic devices. Unlike current testing, which either requires a lab and clinician to interpret results or is a simple qualitative test, éclateral’s o~pal devices are clinical grade, fully quantitative tests that will be available for use in pharmacy, care home, and even private home settings.